Yogaros 5 Tablet contains Rosuvastatin 5 mg, a lipid-lowering agent belonging to the statin class. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, a key enzyme involved in cholesterol biosynthesis in the liver, thereby decreasing cholesterol production and promoting the clearance of LDL particles from the bloodstream. Yogaros 5 is prescribed for primary and secondary prevention of cardiovascular disease, including atherosclerosis, myocardial infarction, and stroke, especially in patients with risk factors such as diabetes, hypertension, or a family history of cardiovascular events. The recommended dosage should be individualized based on patient response and lipid profile, with regular monitoring of liver function tests and lipid levels advised during therapy. Common adverse effects include headache, myalgia, and gastrointestinal disturbances, while serious but rare side effects may involve myopathy or hepatotoxicity. Yogaros 5 Tablet should be used cautiously in patients with hepatic impairment or a history of muscle disorders and is contraindicated during pregnancy and lactation.